Global Drugs for Treating Mental Disorders Market Research Report 2023

Drugs for Treating Mental Disorders Market

The global Drugs for Treating Mental Disorders market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Drugs for Treating Mental Disorders is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Drugs for Treating Mental Disorders is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Drugs for Treating Mental Disorders in Antipsychotics is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Drugs for Treating Mental Disorders include Johnson and Johnson, Pfizer, Eli Lilly, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, Teva Pharmaceutical, Dr. Reddy's Laboratories and Apotex Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Treating Mental Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Treating Mental Disorders.

The Drugs for Treating Mental Disorders market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Drugs for Treating Mental Disorders market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Drugs for Treating Mental Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Drugs for Treating Mental Disorders Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Drugs for Treating Mental Disorders Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Tablets

1.2.3 Capsule

1.2.4 Injection

1.2.5 Solution

1.2.6 Other

1.3 Market by Application

1.3.1 Global Drugs for Treating Mental Disorders Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Antipsychotics

1.3.3 Antidepressants

1.3.4 Antianxiety (Anxiolyitcs)

1.3.5 Anti-Seizure Medications

1.3.6 Stimulants

1.3.7 Cognitive Disorders And Dementia

1.3.8 Sleep Disorder Treatments

1.3.9 Substance Abuse Treatments

1.3.10 Hypnosis And Tranquilizers

1.3.11 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Drugs for Treating Mental Disorders Market Perspective (2018-2029)

2.2 Drugs for Treating Mental Disorders Growth Trends by Region

2.2.1 Global Drugs for Treating Mental Disorders Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Drugs for Treating Mental Disorders Historic Market Size by Region (2018-2023)

2.2.3 Drugs for Treating Mental Disorders Forecasted Market Size by Region (2024-2029)

2.3 Drugs for Treating Mental Disorders Market Dynamics

2.3.1 Drugs for Treating Mental Disorders Industry Trends

2.3.2 Drugs for Treating Mental Disorders Market Drivers

2.3.3 Drugs for Treating Mental Disorders Market Challenges

2.3.4 Drugs for Treating Mental Disorders Market Restraints

3.1 Global Top Drugs for Treating Mental Disorders Players by Revenue

3.1.1 Global Top Drugs for Treating Mental Disorders Players by Revenue (2018-2023)

3.1.2 Global Drugs for Treating Mental Disorders Revenue Market Share by Players (2018-2023)

3.2 Global Drugs for Treating Mental Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Drugs for Treating Mental Disorders Revenue

3.4 Global Drugs for Treating Mental Disorders Market Concentration Ratio

3.4.1 Global Drugs for Treating Mental Disorders Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Drugs for Treating Mental Disorders Revenue in 2022

3.5 Drugs for Treating Mental Disorders Key Players Head office and Area Served

3.6 Key Players Drugs for Treating Mental Disorders Product Solution and Service

3.7 Date of Enter into Drugs for Treating Mental Disorders Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Drugs for Treating Mental Disorders Historic Market Size by Type (2018-2023)

4.2 Global Drugs for Treating Mental Disorders Forecasted Market Size by Type (2024-2029)

5.1 Global Drugs for Treating Mental Disorders Historic Market Size by Application (2018-2023)

5.2 Global Drugs for Treating Mental Disorders Forecasted Market Size by Application (2024-2029)

6.1 North America Drugs for Treating Mental Disorders Market Size (2018-2029)

6.2 North America Drugs for Treating Mental Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Drugs for Treating Mental Disorders Market Size by Country (2018-2023)

6.4 North America Drugs for Treating Mental Disorders Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Drugs for Treating Mental Disorders Market Size (2018-2029)

7.2 Europe Drugs for Treating Mental Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Drugs for Treating Mental Disorders Market Size by Country (2018-2023)

7.4 Europe Drugs for Treating Mental Disorders Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Drugs for Treating Mental Disorders Market Size (2018-2029)

8.2 Asia-Pacific Drugs for Treating Mental Disorders Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2018-2023)

8.4 Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Drugs for Treating Mental Disorders Market Size (2018-2029)

9.2 Latin America Drugs for Treating Mental Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Drugs for Treating Mental Disorders Market Size by Country (2018-2023)

9.4 Latin America Drugs for Treating Mental Disorders Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Drugs for Treating Mental Disorders Market Size (2018-2029)

10.2 Middle East & Africa Drugs for Treating Mental Disorders Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2018-2023)

10.4 Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Johnson and Johnson

11.1.1 Johnson and Johnson Company Detail

11.1.2 Johnson and Johnson Business Overview

11.1.3 Johnson and Johnson Drugs for Treating Mental Disorders Introduction

11.1.4 Johnson and Johnson Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.1.5 Johnson and Johnson Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Detail

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Drugs for Treating Mental Disorders Introduction

11.2.4 Pfizer Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.2.5 Pfizer Recent Development

11.3 Eli Lilly

11.3.1 Eli Lilly Company Detail

11.3.2 Eli Lilly Business Overview

11.3.3 Eli Lilly Drugs for Treating Mental Disorders Introduction

11.3.4 Eli Lilly Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.3.5 Eli Lilly Recent Development

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Detail

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Drugs for Treating Mental Disorders Introduction

11.4.4 GlaxoSmithKline Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.4.5 GlaxoSmithKline Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Detail

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Drugs for Treating Mental Disorders Introduction

11.5.4 AstraZeneca Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.5.5 AstraZeneca Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Detail

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Drugs for Treating Mental Disorders Introduction

11.6.4 Bristol-Myers Squibb Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Teva Pharmaceutical

11.7.1 Teva Pharmaceutical Company Detail

11.7.2 Teva Pharmaceutical Business Overview

11.7.3 Teva Pharmaceutical Drugs for Treating Mental Disorders Introduction

11.7.4 Teva Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.7.5 Teva Pharmaceutical Recent Development

11.8 Dr. Reddy's Laboratories

11.8.1 Dr. Reddy's Laboratories Company Detail

11.8.2 Dr. Reddy's Laboratories Business Overview

11.8.3 Dr. Reddy's Laboratories Drugs for Treating Mental Disorders Introduction

11.8.4 Dr. Reddy's Laboratories Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.8.5 Dr. Reddy's Laboratories Recent Development

11.9 Apotex Inc.

11.9.1 Apotex Inc. Company Detail

11.9.2 Apotex Inc. Business Overview

11.9.3 Apotex Inc. Drugs for Treating Mental Disorders Introduction

11.9.4 Apotex Inc. Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.9.5 Apotex Inc. Recent Development

11.10 Mylan Pharmaceuticals

11.10.1 Mylan Pharmaceuticals Company Detail

11.10.2 Mylan Pharmaceuticals Business Overview

11.10.3 Mylan Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.10.4 Mylan Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.10.5 Mylan Pharmaceuticals Recent Development

11.11 Par Pharmaceutical

11.11.1 Par Pharmaceutical Company Detail

11.11.2 Par Pharmaceutical Business Overview

11.11.3 Par Pharmaceutical Drugs for Treating Mental Disorders Introduction

11.11.4 Par Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.11.5 Par Pharmaceutical Recent Development

11.12 Aurobindo Pharma

11.12.1 Aurobindo Pharma Company Detail

11.12.2 Aurobindo Pharma Business Overview

11.12.3 Aurobindo Pharma Drugs for Treating Mental Disorders Introduction

11.12.4 Aurobindo Pharma Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.12.5 Aurobindo Pharma Recent Development

11.13 Torrent Pharmaceuticals

11.13.1 Torrent Pharmaceuticals Company Detail

11.13.2 Torrent Pharmaceuticals Business Overview

11.13.3 Torrent Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.13.4 Torrent Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.13.5 Torrent Pharmaceuticals Recent Development

11.14 Jubilant Lifesciences

11.14.1 Jubilant Lifesciences Company Detail

11.14.2 Jubilant Lifesciences Business Overview

11.14.3 Jubilant Lifesciences Drugs for Treating Mental Disorders Introduction

11.14.4 Jubilant Lifesciences Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.14.5 Jubilant Lifesciences Recent Development

11.15 Sun Pharmaceutical

11.15.1 Sun Pharmaceutical Company Detail

11.15.2 Sun Pharmaceutical Business Overview

11.15.3 Sun Pharmaceutical Drugs for Treating Mental Disorders Introduction

11.15.4 Sun Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.15.5 Sun Pharmaceutical Recent Development

11.16 Sandoz (Novartis)

11.16.1 Sandoz (Novartis) Company Detail

11.16.2 Sandoz (Novartis) Business Overview

11.16.3 Sandoz (Novartis) Drugs for Treating Mental Disorders Introduction

11.16.4 Sandoz (Novartis) Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.16.5 Sandoz (Novartis) Recent Development

11.17 Hansoh Pharmaceutical

11.17.1 Hansoh Pharmaceutical Company Detail

11.17.2 Hansoh Pharmaceutical Business Overview

11.17.3 Hansoh Pharmaceutical Drugs for Treating Mental Disorders Introduction

11.17.4 Hansoh Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.17.5 Hansoh Pharmaceutical Recent Development

11.18 WATSON Pharmaceuticals

11.18.1 WATSON Pharmaceuticals Company Detail

11.18.2 WATSON Pharmaceuticals Business Overview

11.18.3 WATSON Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.18.4 WATSON Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.18.5 WATSON Pharmaceuticals Recent Development

11.19 Zhejiang Langhua Pharmaceuticals

11.19.1 Zhejiang Langhua Pharmaceuticals Company Detail

11.19.2 Zhejiang Langhua Pharmaceuticals Business Overview

11.19.3 Zhejiang Langhua Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.19.4 Zhejiang Langhua Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.19.5 Zhejiang Langhua Pharmaceuticals Recent Development

11.20 Forest Laboratories

11.20.1 Forest Laboratories Company Detail

11.20.2 Forest Laboratories Business Overview

11.20.3 Forest Laboratories Drugs for Treating Mental Disorders Introduction

11.20.4 Forest Laboratories Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.20.5 Forest Laboratories Recent Development

11.21 H.Lundbeck A/S

11.21.1 H.Lundbeck A/S Company Detail

11.21.2 H.Lundbeck A/S Business Overview

11.21.3 H.Lundbeck A/S Drugs for Treating Mental Disorders Introduction

11.21.4 H.Lundbeck A/S Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.21.5 H.Lundbeck A/S Recent Development

11.22 Amneal Pharmaceuticals

11.22.1 Amneal Pharmaceuticals Company Detail

11.22.2 Amneal Pharmaceuticals Business Overview

11.22.3 Amneal Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.22.4 Amneal Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.22.5 Amneal Pharmaceuticals Recent Development

11.23 Hetero Drugs

11.23.1 Hetero Drugs Company Detail

11.23.2 Hetero Drugs Business Overview

11.23.3 Hetero Drugs Drugs for Treating Mental Disorders Introduction

11.23.4 Hetero Drugs Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.23.5 Hetero Drugs Recent Development

11.24 Macleods Pharmaceuticals

11.24.1 Macleods Pharmaceuticals Company Detail

11.24.2 Macleods Pharmaceuticals Business Overview

11.24.3 Macleods Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.24.4 Macleods Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.24.5 Macleods Pharmaceuticals Recent Development

11.25 Silarx Pharmacueticals

11.25.1 Silarx Pharmacueticals Company Detail

11.25.2 Silarx Pharmacueticals Business Overview

11.25.3 Silarx Pharmacueticals Drugs for Treating Mental Disorders Introduction

11.25.4 Silarx Pharmacueticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.25.5 Silarx Pharmacueticals Recent Development

11.26 Hikma Pharmaceuticals

11.26.1 Hikma Pharmaceuticals Company Detail

11.26.2 Hikma Pharmaceuticals Business Overview

11.26.3 Hikma Pharmaceuticals Drugs for Treating Mental Disorders Introduction

11.26.4 Hikma Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.26.5 Hikma Pharmaceuticals Recent Development

11.27 Lupin Limited

11.27.1 Lupin Limited Company Detail

11.27.2 Lupin Limited Business Overview

11.27.3 Lupin Limited Drugs for Treating Mental Disorders Introduction

11.27.4 Lupin Limited Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.27.5 Lupin Limited Recent Development

11.28 Prinston Pharmaceutical

11.28.1 Prinston Pharmaceutical Company Detail

11.28.2 Prinston Pharmaceutical Business Overview

11.28.3 Prinston Pharmaceutical Drugs for Treating Mental Disorders Introduction

11.28.4 Prinston Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.28.5 Prinston Pharmaceutical Recent Development

11.29 STI Pharma

11.29.1 STI Pharma Company Detail

11.29.2 STI Pharma Business Overview

11.29.3 STI Pharma Drugs for Treating Mental Disorders Introduction

11.29.4 STI Pharma Revenue in Drugs for Treating Mental Disorders Business (2018-2023)

11.29.5 STI Pharma Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Drugs for Treating Mental Disorders Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Tablets

    Table 3. Key Players of Capsule

    Table 4. Key Players of Injection

    Table 5. Key Players of Solution

    Table 6. Key Players of Other

    Table 7. Global Drugs for Treating Mental Disorders Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Drugs for Treating Mental Disorders Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 9. Global Drugs for Treating Mental Disorders Market Size by Region (2018-2023) & (US$ Million)

    Table 10. Global Drugs for Treating Mental Disorders Market Share by Region (2018-2023)

    Table 11. Global Drugs for Treating Mental Disorders Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 12. Global Drugs for Treating Mental Disorders Market Share by Region (2024-2029)

    Table 13. Drugs for Treating Mental Disorders Market Trends

    Table 14. Drugs for Treating Mental Disorders Market Drivers

    Table 15. Drugs for Treating Mental Disorders Market Challenges

    Table 16. Drugs for Treating Mental Disorders Market Restraints

    Table 17. Global Drugs for Treating Mental Disorders Revenue by Players (2018-2023) & (US$ Million)

    Table 18. Global Drugs for Treating Mental Disorders Market Share by Players (2018-2023)

    Table 19. Global Top Drugs for Treating Mental Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Mental Disorders as of 2022)

    Table 20. Ranking of Global Top Drugs for Treating Mental Disorders Companies by Revenue (US$ Million) in 2022

    Table 21. Global 5 Largest Players Market Share by Drugs for Treating Mental Disorders Revenue (CR5 and HHI) & (2018-2023)

    Table 22. Key Players Headquarters and Area Served

    Table 23. Key Players Drugs for Treating Mental Disorders Product Solution and Service

    Table 24. Date of Enter into Drugs for Treating Mental Disorders Market

    Table 25. Mergers & Acquisitions, Expansion Plans

    Table 26. Global Drugs for Treating Mental Disorders Market Size by Type (2018-2023) & (US$ Million)

    Table 27. Global Drugs for Treating Mental Disorders Revenue Market Share by Type (2018-2023)

    Table 28. Global Drugs for Treating Mental Disorders Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 29. Global Drugs for Treating Mental Disorders Revenue Market Share by Type (2024-2029)

    Table 30. Global Drugs for Treating Mental Disorders Market Size by Application (2018-2023) & (US$ Million)

    Table 31. Global Drugs for Treating Mental Disorders Revenue Market Share by Application (2018-2023)

    Table 32. Global Drugs for Treating Mental Disorders Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 33. Global Drugs for Treating Mental Disorders Revenue Market Share by Application (2024-2029)

    Table 34. North America Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 35. North America Drugs for Treating Mental Disorders Market Size by Country (2018-2023) & (US$ Million)

    Table 36. North America Drugs for Treating Mental Disorders Market Size by Country (2024-2029) & (US$ Million)

    Table 37. Europe Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 38. Europe Drugs for Treating Mental Disorders Market Size by Country (2018-2023) & (US$ Million)

    Table 39. Europe Drugs for Treating Mental Disorders Market Size by Country (2024-2029) & (US$ Million)

    Table 40. Asia-Pacific Drugs for Treating Mental Disorders Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 41. Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2018-2023) & (US$ Million)

    Table 42. Asia-Pacific Drugs for Treating Mental Disorders Market Size by Region (2024-2029) & (US$ Million)

    Table 43. Latin America Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 44. Latin America Drugs for Treating Mental Disorders Market Size by Country (2018-2023) & (US$ Million)

    Table 45. Latin America Drugs for Treating Mental Disorders Market Size by Country (2024-2029) & (US$ Million)

    Table 46. Middle East & Africa Drugs for Treating Mental Disorders Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 47. Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2018-2023) & (US$ Million)

    Table 48. Middle East & Africa Drugs for Treating Mental Disorders Market Size by Country (2024-2029) & (US$ Million)

    Table 49. Johnson and Johnson Company Detail

    Table 50. Johnson and Johnson Business Overview

    Table 51. Johnson and Johnson Drugs for Treating Mental Disorders Product

    Table 52. Johnson and Johnson Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 53. Johnson and Johnson Recent Development

    Table 54. Pfizer Company Detail

    Table 55. Pfizer Business Overview

    Table 56. Pfizer Drugs for Treating Mental Disorders Product

    Table 57. Pfizer Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 58. Pfizer Recent Development

    Table 59. Eli Lilly Company Detail

    Table 60. Eli Lilly Business Overview

    Table 61. Eli Lilly Drugs for Treating Mental Disorders Product

    Table 62. Eli Lilly Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 63. Eli Lilly Recent Development

    Table 64. GlaxoSmithKline Company Detail

    Table 65. GlaxoSmithKline Business Overview

    Table 66. GlaxoSmithKline Drugs for Treating Mental Disorders Product

    Table 67. GlaxoSmithKline Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 68. GlaxoSmithKline Recent Development

    Table 69. AstraZeneca Company Detail

    Table 70. AstraZeneca Business Overview

    Table 71. AstraZeneca Drugs for Treating Mental Disorders Product

    Table 72. AstraZeneca Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 73. AstraZeneca Recent Development

    Table 74. Bristol-Myers Squibb Company Detail

    Table 75. Bristol-Myers Squibb Business Overview

    Table 76. Bristol-Myers Squibb Drugs for Treating Mental Disorders Product

    Table 77. Bristol-Myers Squibb Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 78. Bristol-Myers Squibb Recent Development

    Table 79. Teva Pharmaceutical Company Detail

    Table 80. Teva Pharmaceutical Business Overview

    Table 81. Teva Pharmaceutical Drugs for Treating Mental Disorders Product

    Table 82. Teva Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 83. Teva Pharmaceutical Recent Development

    Table 84. Dr. Reddy's Laboratories Company Detail

    Table 85. Dr. Reddy's Laboratories Business Overview

    Table 86. Dr. Reddy's Laboratories Drugs for Treating Mental Disorders Product

    Table 87. Dr. Reddy's Laboratories Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 88. Dr. Reddy's Laboratories Recent Development

    Table 89. Apotex Inc. Company Detail

    Table 90. Apotex Inc. Business Overview

    Table 91. Apotex Inc. Drugs for Treating Mental Disorders Product

    Table 92. Apotex Inc. Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 93. Apotex Inc. Recent Development

    Table 94. Mylan Pharmaceuticals Company Detail

    Table 95. Mylan Pharmaceuticals Business Overview

    Table 96. Mylan Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 97. Mylan Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 98. Mylan Pharmaceuticals Recent Development

    Table 99. Par Pharmaceutical Company Detail

    Table 100. Par Pharmaceutical Business Overview

    Table 101. Par Pharmaceutical Drugs for Treating Mental Disorders Product

    Table 102. Par Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 103. Par Pharmaceutical Recent Development

    Table 104. Aurobindo Pharma Company Detail

    Table 105. Aurobindo Pharma Business Overview

    Table 106. Aurobindo Pharma Drugs for Treating Mental Disorders Product

    Table 107. Aurobindo Pharma Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 108. Aurobindo Pharma Recent Development

    Table 109. Torrent Pharmaceuticals Company Detail

    Table 110. Torrent Pharmaceuticals Business Overview

    Table 111. Torrent Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 112. Torrent Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 113. Torrent Pharmaceuticals Recent Development

    Table 114. Jubilant Lifesciences Company Detail

    Table 115. Jubilant Lifesciences Business Overview

    Table 116. Jubilant Lifesciences Drugs for Treating Mental Disorders Product

    Table 117. Jubilant Lifesciences Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 118. Jubilant Lifesciences Recent Development

    Table 119. Sun Pharmaceutical Company Detail

    Table 120. Sun Pharmaceutical Business Overview

    Table 121. Sun Pharmaceutical Drugs for Treating Mental Disorders Product

    Table 122. Sun Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 123. Sun Pharmaceutical Recent Development

    Table 124. Sandoz (Novartis) Company Detail

    Table 125. Sandoz (Novartis) Business Overview

    Table 126. Sandoz (Novartis) Drugs for Treating Mental Disorders Product

    Table 127. Sandoz (Novartis) Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 128. Sandoz (Novartis) Recent Development

    Table 129. Hansoh Pharmaceutical Company Detail

    Table 130. Hansoh Pharmaceutical Business Overview

    Table 131. Hansoh Pharmaceutical Drugs for Treating Mental Disorders Product

    Table 132. Hansoh Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 133. Hansoh Pharmaceutical Recent Development

    Table 134. WATSON Pharmaceuticals Company Detail

    Table 135. WATSON Pharmaceuticals Business Overview

    Table 136. WATSON Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 137. WATSON Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 138. WATSON Pharmaceuticals Recent Development

    Table 139. Zhejiang Langhua Pharmaceuticals Company Detail

    Table 140. Zhejiang Langhua Pharmaceuticals Business Overview

    Table 141. Zhejiang Langhua Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 142. Zhejiang Langhua Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 143. Zhejiang Langhua Pharmaceuticals Recent Development

    Table 144. Forest Laboratories Company Detail

    Table 145. Forest Laboratories Business Overview

    Table 146. Forest Laboratories Drugs for Treating Mental Disorders Product

    Table 147. Forest Laboratories Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 148. Forest Laboratories Recent Development

    Table 149. H.Lundbeck A/S Company Detail

    Table 150. H.Lundbeck A/S Business Overview

    Table 151. H.Lundbeck A/S Drugs for Treating Mental Disorders Product

    Table 152. H.Lundbeck A/S Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 153. H.Lundbeck A/S Recent Development

    Table 154. Amneal Pharmaceuticals Company Detail

    Table 155. Amneal Pharmaceuticals Business Overview

    Table 156. Amneal Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 157. Amneal Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 158. Amneal Pharmaceuticals Recent Development

    Table 159. Hetero Drugs Company Detail

    Table 160. Hetero Drugs Business Overview

    Table 161. Hetero Drugs Drugs for Treating Mental Disorders Product

    Table 162. Hetero Drugs Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 163. Hetero Drugs Recent Development

    Table 164. Macleods Pharmaceuticals Company Detail

    Table 165. Macleods Pharmaceuticals Business Overview

    Table 166. Macleods Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 167. Macleods Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 168. Macleods Pharmaceuticals Recent Development

    Table 169. Silarx Pharmacueticals Company Detail

    Table 170. Silarx Pharmacueticals Business Overview

    Table 171. Silarx Pharmacueticals Drugs for Treating Mental Disorders Product

    Table 172. Silarx Pharmacueticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 173. Silarx Pharmacueticals Recent Development

    Table 174. Hikma Pharmaceuticals Company Detail

    Table 175. Hikma Pharmaceuticals Business Overview

    Table 176. Hikma Pharmaceuticals Drugs for Treating Mental Disorders Product

    Table 177. Hikma Pharmaceuticals Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 178. Hikma Pharmaceuticals Recent Development

    Table 179. Lupin Limited Company Detail

    Table 180. Lupin Limited Business Overview

    Table 181. Lupin Limited Drugs for Treating Mental Disorders Product

    Table 182. Lupin Limited Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 183. Lupin Limited Recent Development

    Table 184. Prinston Pharmaceutical Company Detail

    Table 185. Prinston Pharmaceutical Business Overview

    Table 186. Prinston Pharmaceutical Drugs for Treating Mental Disorders Product

    Table 187. Prinston Pharmaceutical Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 188. Prinston Pharmaceutical Recent Development

    Table 189. STI Pharma Company Detail

    Table 190. STI Pharma Business Overview

    Table 191. STI Pharma Drugs for Treating Mental Disorders Product

    Table 192. STI Pharma Revenue in Drugs for Treating Mental Disorders Business (2018-2023) & (US$ Million)

    Table 193. STI Pharma Recent Development

    Table 194. Research Programs/Design for This Report

    Table 195. Key Data Information from Secondary Sources

    Table 196. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Drugs for Treating Mental Disorders Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Drugs for Treating Mental Disorders Market Share by Type: 2022 VS 2029

    Figure 3. Tablets Features

    Figure 4. Capsule Features

    Figure 5. Injection Features

    Figure 6. Solution Features

    Figure 7. Other Features

    Figure 8. Global Drugs for Treating Mental Disorders Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Drugs for Treating Mental Disorders Market Share by Application: 2022 VS 2029

    Figure 10. Antipsychotics Case Studies

    Figure 11. Antidepressants Case Studies

    Figure 12. Antianxiety (Anxiolyitcs) Case Studies

    Figure 13. Anti-Seizure Medications Case Studies

    Figure 14. Stimulants Case Studies

    Figure 15. Cognitive Disorders And Dementia Case Studies

    Figure 16. Sleep Disorder Treatments Case Studies

    Figure 17. Substance Abuse Treatments Case Studies

    Figure 18. Hypnosis And Tranquilizers Case Studies

    Figure 19. Other Case Studies

    Figure 20. Drugs for Treating Mental Disorders Report Years Considered

    Figure 21. Global Drugs for Treating Mental Disorders Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 22. Global Drugs for Treating Mental Disorders Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 23. Global Drugs for Treating Mental Disorders Market Share by Region: 2022 VS 2029

    Figure 24. Global Drugs for Treating Mental Disorders Market Share by Players in 2022

    Figure 25. Global Top Drugs for Treating Mental Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Treating Mental Disorders as of 2022)

    Figure 26. The Top 10 and 5 Players Market Share by Drugs for Treating Mental Disorders Revenue in 2022

    Figure 27. North America Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. North America Drugs for Treating Mental Disorders Market Share by Country (2018-2029)

    Figure 29. United States Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Canada Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Europe Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Europe Drugs for Treating Mental Disorders Market Share by Country (2018-2029)

    Figure 33. Germany Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. France Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. U.K. Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. Italy Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Russia Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Nordic Countries Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Asia-Pacific Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Asia-Pacific Drugs for Treating Mental Disorders Market Share by Region (2018-2029)

    Figure 41. China Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Japan Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. South Korea Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Southeast Asia Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. India Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Australia Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Latin America Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. Latin America Drugs for Treating Mental Disorders Market Share by Country (2018-2029)

    Figure 49. Mexico Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 50. Brazil Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 51. Middle East & Africa Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 52. Middle East & Africa Drugs for Treating Mental Disorders Market Share by Country (2018-2029)

    Figure 53. Turkey Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 54. Saudi Arabia Drugs for Treating Mental Disorders Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 55. Johnson and Johnson Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 56. Pfizer Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 57. Eli Lilly Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 58. GlaxoSmithKline Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 59. AstraZeneca Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 60. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 61. Teva Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 62. Dr. Reddy's Laboratories Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 63. Apotex Inc. Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 64. Mylan Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 65. Par Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 66. Aurobindo Pharma Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 67. Torrent Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 68. Jubilant Lifesciences Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 69. Sun Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 70. Sandoz (Novartis) Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 71. Hansoh Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 72. WATSON Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 73. Zhejiang Langhua Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 74. Forest Laboratories Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 75. H.Lundbeck A/S Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 76. Amneal Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 77. Hetero Drugs Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 78. Macleods Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 79. Silarx Pharmacueticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 80. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 81. Lupin Limited Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 82. Prinston Pharmaceutical Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 83. STI Pharma Revenue Growth Rate in Drugs for Treating Mental Disorders Business (2018-2023)

    Figure 84. Bottom-up and Top-down Approaches for This Report

    Figure 85. Data Triangulation

    Figure 86. Key Executives Interviewed